Brodszky, Valentin; Baji, Petra; Balogh, Orsolya; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 65-71
The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European...